Objective: This research examined electronic cigarette (e-cigarette) use by individuals in treatment for substance abuse, a population with a high prevalence of tobacco use and poor smoking cessation outcomes. Methods: We surveyed 1127 individuals from 24 substance abuse treatment centers across the United States. Bivariate analyses and logistic regression were used to examine factors associated with daily (N = 87) versus weekly (N = 81) e-cigarette use. Results: Among the full sample, 59.8% reported any lifetime use of e-cigarettes, with 23.6% reporting past 30-day use. Daily e-cigarette users were more likely to have used second-generation, tank-type e-cigarettes, χ
Introduction
Prevalence of tobacco use is high among individuals with drug and alcohol dependence and highest among those seeking treatment for substance abuse. [1] [2] [3] Consequently, tobacco-related diseases is a leading causes of death in this population. 4, 5 Individuals with substance use disorders also have poorer smoking cessation outcomes compared to general population smokers. [6] [7] [8] Tobacco use is often overlooked within drug abuse treatment programs, 9 despite evidence that smoking cessation does not interfere with and may actually improve treatment outcomes. [6] [7] [8] There is controversy regarding the potential benefits and harms of electronic cigarettes (e-cigarettes) and debate about their effectiveness for smoking cessation. [10] [11] [12] It is not known to what extent e-cigarettes may benefit or interfere with attempts to reduce tobacco use among individuals in substance abuse treatment. There is a need to better understand e-cigarette use within this population in order to help treatment program counselors and administrators navigate e-cigarette use with patients and develop effective e-cigarette use policies.
We previously reported a high prevalence of e-cigarette use among a large national sample of individuals in treatment for substance abuse. 13 This finding was consistent with two studies among similar but localized drug treatment populations. 14, 15 We found that a majority of e-cigarette users in substance abuse treatment also smoked tobacco cigarettes (ie, were dual users), were heavier cigarette smokers, were more likely to have tried nicotine replacement therapy (NRT), and may have been trying to quit or reduce their tobacco use. Daily (vs. non-daily) e-cigarette users were also more likely to use e-cigarettes to reduce health risks and to quit or reduce tobacco cigarette use. 13 Participants most often reported using e-cigarettes at times or places they could not use tobacco. One concern is that e-cigarettes could potentially interfere with smoking cessation efforts at substance abuse treatment facilities.
Several studies have found higher quit rates reported among daily e-cigarette users, and users of second-generation, tank-type e-cigarette devices. 16, 17 These findings highlight the need to understand which e-cigarette products (eg, device type, flavor, and nicotine concentration) are being used among substance abuse treatment clients as well as to explore differences based on frequency of use.
The present study extends our previous work by analyzing additional e-cigarette questions added to the survey during the second year of data collection to explore device characteristics, nicotine concentrations, use of flavors, patterns of use, and frequency of device breakage to better understand how e-cigarettes are used among individuals in treatment for drug and alcohol dependence.
The goals of this study were to (1) examine e-cigarette use and device type characteristics in a national sample of persons enrolled in substance abuse treatment; (2) explore demographic and use characteristics associated with daily versus weekly e-cigarette users; and (3) determine frequency of e-cigarette breakage among users. For this article, we focused on differences between individuals who reported daily versus weekly e-cigarette use, excluding less than weekly users, those who were likely only experimenters. We hypothesized that e-cigarette use characteristics would differ based on frequency of use and that daily e-cigarette users would be more likely to be former cigarette smokers, consistent with reports in the general population.
Methods

Participants and Recruitment Procedure
The e-cigarette findings reported here represent a subcomponent of a larger parent study, which explored tobacco use among individuals in substance abuse treatment through a series of three annual surveys conducted in 24 substance abuse treatment centers (10 residential, 7 methadone maintenance, and 7 outpatient clinics) affiliated with the NIDA Clinical Trials Network (CTN). See Gerstein and Lewin 18 for description of these different types of substance abuse treatment clinics. Briefly, methadone maintenance programs are ambulatory treatment for opiate dependence, involving daily administration of methadone at the clinic site. Non-methadone outpatient and residential programs include treatment for opiate dependence as well as other drugs of abuse. Non-methadone outpatient treatment programs generally involve one or two visits per week, while residential programs involve highly structured daily treatment with the clients living onsite. Participating clinics were selected to be representative of drug treatment centers in the NIDA CTN; however, data were collected as a convenience sample within each clinic site. All sites were located in the United States and had at least 60 active clients when screened for eligibility. A detailed description of the criterion, client recruitment, and, and data collection procedures is reported in Guydish et al. 19 The 2015 survey, wave 2 of the parent study, was modified to add additional questions about e-cigarettes. We recruited a convenience sample within each clinic during annual on-site visits. All clients at each center (regardless of smoking status) were eligible to participate in the survey as long as they were physically present the day of the site visit and had been in treatment at that center for at least 10 days. The 10-day time in treatment criterion ensured that clients had time to become aware of program use tobacco policies. The research team explained the study to all clients who expressed interest to participate and completed informed consent procedures. No information was recorded for those uninterested in the survey; however, all those who completed the consent process also completed the survey. The 2015 survey sampled 1127 individuals from a total estimated population of 6801 total clients serviced by these programs (approximately 16.6% of the total active clients treated in these 24 programs during the survey year). The number of participants recruited per clinic ranged from 31 to 55, with a median of 48. Each participant received a $20 gift card for participating and each treatment program received a $2000 program incentive. All procedures were approved by the Institutional Review Board of the University of California, San Francisco.
Procedure and Measures
Surveys were prepared using Qualtrics™ (Provo, Utah) software and were self-administered during an on-site visit to each clinic, from April to December 2015, using iPads linked to a secure university server.
The survey included demographic information (age, gender, race/ ethnicity, employment status, and education) and primary drug for which the client sought treatment. Self-reported smoking status was characterized as current, former, or never cigarette smoker. Current smokers were defined as having smoked more than 100 cigarettes in their lifetime and also reporting being a current cigarette smoker. There were four individuals who reported being current smokers but smoked less than 100 cigarettes in their lifetime; these individuals were reclassified as never smoker for the analyses. Individuals were also asked to report their general health (using a scale from excellent to poor), and the number of days in the past month their mental and physical health was not good. 20 All participants were asked to report any lifetime use of e-cigarettes. Those reporting any lifetime e-cigarette use were asked whether they had used e-cigarettes in the past 30 days. Those reporting past 30-day e-cigarette use were then asked about frequency of e-cigarette use (daily, weekly, or < weekly) and the number of months they had been using e-cigarettes.
Participants who reported weekly or greater e-cigarette use were asked additional questions about device type, nicotine concentration, flavoring, patterns of use, reasons for use, money spent on e-cigarettes/accessories, and device breakage as described subsequently. During pilot testing, the more detailed e-cigarette question was asked all past 30 day e-cig users. Many of the individuals who reported using e-cigarettes less than weekly said they did not really use them and only tried them once or twice and did not know how to answer these questions. As a result, we modified the survey design to only ask these more detailed questions only of individuals who reported weekly or greater e-cigarette use. Participants reported the primary device type they used as (a) cigarette-shaped disposable e-cigarette; (b) cigarette-shaped e-cigarette with a rechargeable battery and disposable cartridges; (c) larger than a cigarette with a button to press prior to inhalation; or (d) "I don't know". Participants reported the concentration of nicotine usually used (0 mg, 1-6 mg, 7-12 mg, 13-18 mg, 19-24 mg, or "I don't know"), their usual e-cigarette flavor (tobacco, mint/menthol/wintergreen, fruit/berry, candy/ dessert, alcohol/ cocktail, coffee, other, or "I don't know"), and reasons for use: (a) at times or places you can't smoke cigarettes; (b) as a tool to reduce health risks; (c) as a tool to quit or reduce cigarette smoking; (d) because they have good flavors; (e) because they don't smell bad; (f) because they cost less than tobacco cigarettes, and (g) other reason. Participants reported how much money they spent in the past month on e-cigarettes and accessories.
E-cigarettes can be used in a variety of patterns, from distinct sessions of multiple puffs (like a cigarette) to continuously at various intervals. 18 We developed a measure to assess differences in patterns of use. Individuals were asked how they usually used their e-cigarette: (a) continuously throughout the day; (b) distinct smoking bouts that are shorter than smoking a tobacco cigarette; (c) distinct smoking bouts similar to smoking a tobacco cigarette; or (c) "other."
During the preliminary focus groups, a number of individuals reported having e-cigarette devices break leading to their switching back to tobacco cigarettes after their e-cigarette devices had broken. Participants were asked if they had an e-cigarette/ vape pen device that had broken. Those reporting "yes" were asked to report what they did when their e-cigarette/vape pen broke: (a) buy a new e-cigarette device; (b) switch to smoking tobacco cigarettes; (c) switch to another nicotine replacement product (eg, patch or gum); or (d) stopped using all nicotine or tobacco products.
Data Analysis
The subsample of 168 participants who reported using e-cigarettes weekly or more (87 daily users and 81 weekly users) were used in the current analyses. Excluded from analyses in the design phase were those reporting less than weekly e-cigarette use (n = 98), as these participants did not receive the more detailed e-cigarette survey items. E-cigarette device types were collapsed into two categories: first-generation cig-a-like models (with disposable or replacement nicotine cartridges) and second-generation tank-type models (with a refillable canister for nicotine e-juice).
We conducted exploratory bivariate analyses (t-tests for continuous variables and Pearson's chi-square tests for categorical variables) to identify variables associated with daily versus weekly e-cigarette use at p < .10 to include in a logistic regression. 22 Means are presented ± standard deviation (SD). The p < .10 level for variable to include in the logistic regression model was used to avoid missing variables that might be associated with the outcome by being too strict as recommended by Hosmer and Lemeshow. 23 A logistic regression model was used to estimate the association of each predictor controlling for key demographic variables. The predictors identified thought the bivariate analyses and included in the logistic regression model were clinic type, current cigarette smoking status, and past month days with poor mental health. Because substance abuse clinic types differ in employment status (higher employment in methadone and outpatient compared to residential treatment 24 ), clinic type but not employment status was included in the model. In addition, the bivariate analyses identified clinic type but not primary drug as being different between daily and weekly e-cigarette users. As these variables are confounded, we included only clinic type in the model. Days of poor physical health was correlated with days of poor mental health (r = .37, p < .001) and for this reason was not included in the model. Three never tobacco cigarette smokers used e-cigarettes weekly or greater and were excluded from the regression model. Statistical analyses were performed using SPSS 24 (IBM Corporation, Armonk, New York).
Results
Sample Characteristics
The full sample was 46.3% female, 65.3% White, 19.3% African American, and 12.6% Hispanic or Latino, with a mean age of 38.6 ± 11.9 years. Overall, 21.8% had less than a high school degree, 63.3% had a high school or GED equivalent, and 14.9% had a college degree. There were 38.1% from residential treatment, 30.7% from outpatient treatment, and 31.2% from methadone treatment. For the full sample, 76.4% were current cigarette smokers, 14.8% were former cigarette smokers, and 8.9% were never smokers. Current cigarette smokers smoked an average of 13.4 ± 8.6 cigarettes per day on 6.6 ± 1.3 days per week.
Distribution of race and ethnicity was similar to what was reported by the Substance Abuse and Mental Health Services Administration (SAMHSA), although our overall sample had a higher prevalence of women and methadone programs were overrepresented in our sample, as 7 of the 24 programs were methadone programs. 25 
Prevalence and Frequency of e-Cigarette Use
For the full sample, 59.8% (n = 674) reported any lifetime use of e-cigarettes, with 23.6% (n = 266) reporting e-cigarette use in the past month. This is similar to findings from the 2014 data, although compared to the previous year there was a slight increase in number of individuals reporting any lifetime use of e-cigarettes (2014 = 55.5%), but a decrease in past month e-cigarette use (2014 = 30.5%). 13 Among past month e-cigarette users, 32.7% reported daily use (n = 87), 30.5% reported weekly use (n = 81), and 36.8% reported less than weekly use (n = 98).
Daily Versus Weekly e-Cigarette Users
Bivariate comparisons between daily and weekly e-cigarette users (N = 168) are presented in Table 1 . There were significant differences between daily and weekly e-cigarette users for clinic type, χ 2 (2,N = 168) = 11.3, p = .003; daily e-cigarette users were more likely to be in methadone treatment, while weekly e-cigarette users were more likely to be in residential treatment. Daily e-cigarette users were also more likely to have current employment versus weekly e-cigarette users, χ = 17.0, p < .001. As mentioned earlier, only 3 individuals who reported weekly or greater e-cigarette use were never tobacco cigarette smokers.
Daily e-cigarette users reported significantly fewer days in the past month with poor physical health (3.8 ± 7.4 vs. 6.6 ± 9.4; t (168) = −2.09, p = .04) and poor mental health (6.2 ± 8.5 vs 9.2 ± 10.2; t (168) = −2.03, p = .04) compared to weekly e-cigarette users. However, there was no significant difference between groups for the self-reported general health assessment.
A logistic regression model (Table 2 ) of daily versus weekly e-cigarette users estimated the association of each predictor controlling for variables identified in the bivariate analyses (p < .10). Adjusting for clinic type and number of poor mental health days, daily e-cigarette users were more likely to be former smokers (AOR = 6.37, p = .002). The same relationship was found when the model was run with employment instead of clinic type (data not shown). Controlling for number of poor mental health days and tobacco smoking status, daily e-cigarette users were significantly more likely to be from methadone versus residential treatment (AOR = 2.40, p = .04). No difference was found for daily e-cigarette use between outpatient and residential treatment.
Daily and weekly e-cigarette users differed on a number of variables related to both device type and use characteristics (Table 3) . A higher proportion of daily e-cigarette users reported using their device continuously throughout the day, with only a few puffs each time, χ 2 (4,N = 168) = 16.7, p = .002. Daily e-cigarette users were more likely to use e-cigarettes as a way to reduce health risks (50.6% vs. 32.1%), χ
2
(1,N = 168) = 5.9, p = .02, and because they cost less than tobacco cigarettes (37.9% vs. 21.0%), χ
(1,N = 168) = 5.8, p = .02, while weekly users were more likely to use e-cigarettes at times or places they could not smoke tobacco cigarettes (71.6% vs. 56.3%), χ
(1,N = 168) = 4.2, p = .04). Daily and weekly groups both reported similar use of e-cigarettes as a way to reduce or quit tobacco cigarettes (53.0% overall), because they have good flavors (41.1% overall) or because they do not leave you smelling bad (44.6% overall); group means and statistics are presented in Table 3 . A majority of participants reported using tank-type e-cigarette devices compared to cig-a-like, first-generation type models (82.4% overall). Daily users reported a higher prevalence of using tank-type models versus only cig-a-like type devices (92.0% vs. 71.8%), χ
(1,N = 165) = 11.5, p = .001, and spent more money per month on e-cigarettes compared to weekly e-cigarette users. Daily users also reported using more types of e-juice flavors (2.2 ± 1.3 vs. 1.8 ± 1.4), t (168) = 2.15, p = .03, and were more likely to have used tobacco flavor, fruit/ berry flavor, or select "other" flavor compared to weekly users. Overall, users of tank-type e-cigarettes were more likely to use more flavors compared to users of first-generation cig-a-like devices (1.2 ± 1.0 vs. 2.2 ± 1.4), t (168) = −3.69, p < .001).
Having an e-Cigarette Device That Broke
Over half (57.7%) of the daily and weekly e-cigarette users reported having an e-cigarette device that broke. Among those who reported having an e-cigarette device that broke (n = 97), 68.0% reported buying a new e-cigarette device, 24.7% switched to smoking tobacco cigarettes, 2.1% switched to a nicotine replacement product (e, patch or gum), and 2.1% stopped using all nicotine or tobacco products.
Discussion
Replicating previous work, 13 we found a high prevalence of e-cigarette use among individuals in treatment for substance abuse (over half the sample reported any lifetime use and 23.6% reported use in the past 30 days). Daily versus weekly e-cigarette users were more likely to be former cigarette smokers. This finding is consistent with reports that among e-cigarette users, daily users may be the most likely to quit tobacco cigarettes. 16, 17 However, the majority of both daily and weekly e-cigarette users in our sample were current cigarette smokers, suggesting that most e-cigarette users had not quit tobacco. Our findings suggest that a subpopulation of daily e-cigarette users in addiction treatment may be more likely to benefit from their use. Understanding the efficacy of e-cigarettes for tobacco cessation remains a target for future research both in the general population and among vulnerable populations such as individuals in substance abuse treatment.
We previously reported that daily versus nondaily users were more likely to report using e-cigarettes as a way to quit tobacco cigarettes. 13 In the current analyses, including only daily and weekly e-cigarette users, there was no difference in the use of e-cigarettes as a way to quit tobacco cigarettes. The higher prevalence of former smokers among daily versus weekly e-cigarette users suggests that there may be differences related to successfully quitting tobacco cigarettes, despite similar reported use of e-cigarettes as a way to quit or reduce tobacco cigarettes. Daily e-cigarette users were more likely to report using e-cigarettes as a way to reduce health risk, and because they cost less than tobacco cigarettes, while weekly e-cigarette users were more likely to use e-cigarettes at times and places where they could not smoke tobacco cigarettes. These differences in reasons for use could contribute to the higher prevalence of former smokers among the daily e-cigarette users.
Daily e-cigarette users were more likely to report using their e-cigarette continuously throughout the day, while weekly e-cigarette users were more likely to use e-cigarettes at times or places where they could not smoke tobacco cigarettes. This is consistent with reports that experience using an e-cigarette device can lead to significant differences in the way individuals use e-cigarettes. 26, 27 While more information is needed, this research indicates that differences in patterns of e-cigarette use may explain differences in efficacy of e-cigarettes for smoking cessation.
We found a higher prevalence of daily e-cigarette users in methadone treatment, when compared to those in residential treatment, but not outpatient treatment programs. Several factors may contribute to this difference. Daily versus weekly e-cigarette users were more likely to be employed and may have greater ability to purchase e-cigarettes. The lowest rates of current employment were among individuals in residential treatment (13.3%) compared to methadone (38.9%) and outpatient treatment (50.0%), as expected. 24 Outpatient treatment, which did not differ from residential treatment, had the highest rates of employment, suggesting that employment was not the only factor influencing differences in e-cigarette use frequency by clinic type.
Policies regarding e-cigarette use at the program level were evolving and often not fully established at the time of our visits in 2015.
Interviews with program directors indicated that e-cigarettes were treated similar to tobacco cigarettes. There were two residential programs that indicated e-cigarette use was not allowed. More restrictive policies in residential treatment programs could also contribute to lower levels of e-cigarette use among individuals in residential programs. However, outpatient treatment programs did not differ from residential treatment in e-cigarette use frequency, suggesting that other factors in addition to program level policies likely contribute to these differences. There is a need to better understand how program-level policies affect e-cigarette use.
The majority of daily and weekly e-cigarette users in drug treatment used some type of second-generation "tank-type" device versus first-generation "cig-a-like"-type products. This is consistent with reports that experienced e-cigarette users have a higher prevalence of using tank-type devices. 28 In addition to device type, there were a number of differences in e-cigarette use characteristics between the daily and weekly e-cigarette users. In our sample, individuals were able to select all e-juice flavors used. Daily versus weekly e-cigarette users reported using more types of e-juice flavors overall. Among weekly or greater e-cigarette users, individuals that used of tank-type devices used more flavors overall compared to users of cig-a-like models. Certain e-cigarette devices, particularly cig-a-like models, may differ in flavor choices, and this likely contributes to the relationship between device type and use of flavors. Understanding the relationship between flavors and use patterns remains an important area for future research. Interestingly, especially among weekly users, more individuals did not know the concentration of nicotine used, than what flavor they used. E-cigarette users may be more attuned to flavor versus nicotine concentration, and this highlights a need to better educate e-cigarette users about nicotine concentration, as this could influence efficacy for smoking cessation. One area of concern among individuals in treatment for substance abuse was the use of alcohol/cocktail flavors, which may serve as cues for relapse among those with alcohol related problems. However, in this sample of regular e-cigarette users in substance abuse treatment, very few (3.0%) reported using these flavors.
A majority of individuals reported spending less than US$50 per month, indicating that for most daily or weekly e-cigarette users costs were relatively low. Cost burden could have a role in use of e-cigarettes or the decision to use them instead of tobacco cigarettes, particularly among individuals with lower socioeconomic status. For example, the average price of a pack of cigarettes in the United States in 2014 was ~US$6.28.
29 While e-cigarettes may be less expensive than tobacco cigarettes, and 37.9% of daily users reported this as a reason for their use, a majority of users were dual tobacco and e-cigarette users. Our study did not assess how much clients spent on tobacco cigarettes. Future research is needed to evaluate the cost burden of dual use of e-cigarettes and tobacco cigarettes compared to either product used alone.
Half of weekly and daily e-cigarette users reported having an e-cigarette device that broke. Tank-type e-cigarette devices have a higher up-front cost (e.g. purchasing the device) but lower use cost to purchase "e-juice" (nicotine liquid) only. Device reliability represents an area for future regulation and is particularly important among individuals with lower household incomes. We found that 24% of those who reported having an e-cigarette device break switched to only smoking tobacco cigarettes. This is a concern for those using e-cigarettes to quit tobacco cigarettes and highlights the importance of device stability if e-cigarettes are used to reduce or quit tobacco cigarettes.
This work is limited by the cross-sectional design, in which changes in cigarette or e-cigarette use could not be assessed. Longitudinal studies are needed to understand trajectories of e-cigarette use and quit rates among substance abuse treatment populations. Another limitation is that there are multiple different types of e-cigarettes devices, as our analyses lacked power to explore differences between device types and use characteristics. Finally, the participating clinics were selected to be representative of drug treatment centers in the NIDA CTN; however, we recruited a convenience sample within each clinic site, and the client sample may not be nationally representative. Methadone clinics were one of the three treatment programs surveyed in our study. For this reason, there was a higher prevalence of individuals reporting opiates and reduced prevalence of alcohol as the primary drug for which treatment was received compared to other surveys among individuals in treatment for drug and alcohol dependence. 25 Distribution of race and ethnicity was similar to what was reported by SAMHSA, although our study had a higher proportion of women. 25 Despite this limitation, there are a number of challenges to sampling individuals within active drug treatment, and the current survey design allowed for data collection from a large sample of individuals currently in substance abuse treatment.
In conclusion, we found differences in the device and use characteristics of daily versus weekly e-cigarette users in substance abuse treatment. Daily e-cigarette users were more likely to be former cigarette smokers, although the majority of e-cigarette users were current tobacco cigarette smokers. Efficacy of e-cigarettes for smoking cessation and device reliability remain important issues in the debate over how to regulate e-cigarettes. Individual substance abuse treatment programs need to evaluate the potential benefits versus the potential harms when developing policies regarding e-cigarette use.
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